CoChat

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Published version of a preprint

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Abstract

The PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in PI3K, PTEN, and B-cell receptor signaling, leading to dysregulation of eIF4A (through its regulators, eIF4B, eIF4G, and PDCD4) and the eIF4F complex. Activation of eIF4F has a direct role in tumorigenesis due to increased synthesis of oncogenes that are dependent on enhanced eIF4A RNA helicase activity for translation. eFT226, which inhibits translation of specific mRNAs by promoting eIF4A1 binding to 5′-untranslated regions (UTR) containing polypurine and/or G-quadruplex recognition motifs, shows potent antiproliferative activity and significant in vivo efficacy against a panel of diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma models with ≤1 mg/kg/week intravenous administration. Evaluation of predictive markers of sensitivity or resistance has shown that activation of eIF4A, mediated by mTOR signaling, correlated with eFT226 sensitivity in in vivo xenograft models. Mutation of PTEN is associated with reduced apoptosis in vitro and diminished efficacy in vivo in response to eFT226. In models evaluated with PTEN loss, AKT was stimulated without a corresponding increase in mTOR activation. AKT activation leads to the degradation of PDCD4, which can alter eIF4F complex formation. The association of eFT226 activity with PTEN/PI3K/mTOR pathway regulation of mRNA translation provides a means to identify patient subsets during clinical development.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-19-0973

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 53

Metadata

Authors
Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., Chiang, G. G., Gerson-Gurwitz, A., Wegerski, C. J., Nevarez, A., Clarine, J., Sperry, S., Xiang, A., Nilewski, C., Packard, G. K., Michels, T., Tran, C., Sprengeler, P. A., Ernst, J. T., Reich, S. H., & Webster, K. R.
Affiliations
  • eFFECTOR Therapeutics (United States) (US)
  • eFFECTOR Therapeutics, Inc., San Diego, California.
Corresponding author
Thompson, Peggy A.
Venue
Molecular Cancer Therapeutics
Published
2021-01-01
Volume
20
Issue
1
Pages
26-36
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3092340104
Cited by
50
References
38
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 10 · 2022: 14 · 2021: 11
FWCI
2.92
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
eFFECTOR Therapeutics
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
mRNA translation, B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, PI3K/AKT/mTOR pathway, PTEN loss, PDCD4, eIF4F, 5' untranslated region, G-quadruplex, predictive biomarkers, drug sensitivity and resistance, antiproliferative activity
MeSH terms
Animals, Female, Humans, Oncogenes, RNA, Messenger, Protein Biosynthesis, Biomarkers, Tumor, Lymphoma, B-Cell, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Eukaryotic Initiation Factor-4A, Cell Line, Tumor, PTEN Phosphohydrolase, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. https://app.cochat.ai/papers/10.1158/1535-7163.mct-19-0973
The paper
Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., Chiang, G. G., Gerson-Gurwitz, A., Wegerski, C. J., Nevarez, A., Clarine, J., Sperry, S., Xiang, A., Nilewski, C., Packard, G. K., . . . Webster, K. R. (2021). Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-19-0973

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.